NCT07241533 Asiaticoside for Treating Overweight/Obesity
| NCT ID | NCT07241533 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Zhongshan Hospital |
| Condition | Overweight , Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-12-01 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Centella asiatica is a traditional herbal medicine widely used in China and Southeast Asia for treating various conditions. Preclinical studies have shown that madecassic acid glycosides, including asiaticoside and madecassoside, can significantly reduce body weight gain, adipose tissue mass, and serum triglyceride levels in high-fat diet-induced obese mice. These compounds also improve hepatic steatosis and insulin resistance. This exploratory, interventional study aims to evaluate the clinical efficacy of orally administered asiaticoside tablets in adults with overweight or obesity.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older, male or female. * Overweight or obesity, defined as a body mass index (BMI) of 24.0-45.0 kg/m². * Able and willing to provide written informed consent. Exclusion Criteria: * Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other severe infectious or immunocompromising conditions. * Severe liver injury (AST or ALT \> 3 times the upper limit of normal) or severe renal dysfunction/end-stage renal disease (eGFR \< 30 mL/min/1.73 m²). * Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months. * Severe gastrointestinal disorders, or a history of gastrointestinal surgery within the past year. * Secondary causes of obesity, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, acromegaly; or drug-induced obesity (e.g., antipsychotics, glucocorticoids). * Currently receiving other anti-obesity treatments, a previous history of bariatric surgery, or a \>5% reduction in body weight within the past 3 months. * Current smoker or habitual smoker within the past 3 months. * type 1 or type 2 diabetes mellitus or currently taking hypoglycemic medications. * Pregnancy or planning pregnancy, or breastfeeding. * Unable to complete a 3-month follow-up due to health conditions or relocation. * Participation in any clinical study within the past 4 weeks. * Other conditions considered by investigators as unsuitable for participation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07241533 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Overweight , Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07241533 currently recruiting?
Yes, NCT07241533 is actively recruiting participants. Contact the research team at jiang.jingjing@zs-hospital.sh.cn for enrollment information.
Where is the NCT07241533 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07241533 clinical trial?
NCT07241533 is sponsored by Shanghai Zhongshan Hospital. The trial plans to enroll 30 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.